Phase IIb clinical

Related by string. phase IIb clinical * phase . phases . Phases . PHASE : Phase III clinical trials . Phase III trials . pivotal Phase III . ongoing Phase 1b / IIB . IIBS : Phase IIb trial . Phase IIb . initiate Phase IIb / clinicals . CLINICAL . Clinicals : Phase III clinical . Phase 2b clinical . placebo controlled clinical trials * Phase IIb clinical trials . Phase IIb Clinical Trial *

Related by context. All words. (Click for frequent words.) 82 Phase 2b clinical 82 Phase IIb 81 Phase 2a clinical 81 Phase III clinical 80 phase IIa clinical 80 pivotal Phase III 79 Phase 1b clinical 79 phase IIb clinical 79 Phase IIa clinical 79 Phase IIb trial 78 phase IIb 78 Phase 2b study 78 Phase IIa 77 Phase Ib clinical 77 Phase 2a 77 Phase 2b trial 77 Phase 2a trial 77 Phase 2b 77 Phase IIa trial 77 Phase Ib 76 phase IIa 75 Phase IIIb clinical 74 Phase 1b 74 Phase IIb trials 74 Phase III 74 phase 2a 73 Phase III clinical trials 73 Phase 1b trial 72 confirmatory Phase III 72 pivotal Phase 71 clinical trial 71 Phase 1a clinical 71 Phase Ib II 71 phase IIb trial 71 Phase Ia 71 registrational 70 multicenter clinical 70 multicenter Phase II 70 APEX PD 70 Phase III pivotal 70 placebo controlled clinical 70 multicenter Phase 70 Phase 1a 70 randomized Phase III 69 randomized Phase IIb 69 confirmatory Phase 3 69 Phase II 69 oral ridaforolimus 69 Phase IIB 69 multiple ascending dose 69 dose escalation trial 69 Phase 2b clinical trials 69 placebo controlled Phase 69 Phase Ib study 68 Phase IIa trials 68 dirucotide 68 Phase III trials 68 glufosfamide 68 dose escalation study 68 dose escalation Phase 68 placebo controlled Phase III 68 phase Ib clinical 68 alvespimycin 68 randomized Phase 68 Phase #b/#a 68 phase Ib 68 BRIM3 68 Phase III confirmatory 68 IIa trial 68 bicifadine 68 Phase IIIb 67 Phase #b/#a clinical 67 phase IIb study 67 elotuzumab 67 JAK inhibitor 67 dose escalation clinical 67 Phase IIb III 67 IIa clinical trial 67 FOLOTYN ® 67 Phase Ib IIa 67 ADVANCE PD 67 INCB# [001] 67 registrational trial 66 MEND CABG 66 Alzhemed TM 66 Phase Ib clinical trials 66 SUCCEED trial 66 teduglutide 66 investigational drug 66 Phase IIb clinical trials 66 PRX # 66 lomitapide 66 PREOS 66 AQ4N 66 Zenvia Phase III 66 Phase III randomized controlled 66 BRIM2 65 Zerenex 65 initiate Phase IIb 65 clinical trials 65 tanespimycin 65 phase IIIb 65 relapsed refractory multiple myeloma 65 Amrubicin 65 Zenvia ™ 65 pharmacokinetic PK study 65 Fx #A 65 cetrorelix 65 placebo controlled 65 Corlux 65 investigational compound 65 MIST II 65 double blinded placebo 65 pharmacokinetic PK 65 Phase 2b kidney transplant 65 Archexin 65 randomized Phase 2b 65 PDE4 inhibitor 65 confirmatory clinical 65 assessing T DM1 65 NP2 Enkephalin 64 BCX# 64 randomized multicenter 64 CEQ# 64 multicenter phase 64 CB2 selective receptor agonist 64 virus HCV protease inhibitor 64 GALNS 64 Bicifadine 64 multicenter randomized placebo controlled 64 ongoing Phase 1b 64 forodesine 64 rALLy clinical trial 64 PEG PAL 64 single ascending dose 64 brivaracetam 64 tesmilifene 64 Phase #/#a 64 TMC# C# 64 ADAGIO study 64 fostamatinib 64 Androxal TM 64 Phase 1b dose escalation 64 AEGR 64 Phenoptin 64 randomized controlled Phase 64 clinical pharmacology studies 64 preclinical 64 diabetic neuropathic pain 64 ocrelizumab 64 denufosol 64 Phase IIa clinical trials 64 Dacogen injection 64 axitinib 64 dextromethorphan quinidine 64 pivotal bioequivalence 64 Phase IIIb study 64 vidofludimus 64 TG MV 64 phase IIb III 64 ELACYT 64 GLPG# 64 MEK inhibitor RDEA# 64 Aurexis 63 PLK1 SNALP 63 reslizumab 63 cannabinor 63 HGS ETR1 63 LUX Lung 63 opioid induced bowel dysfunction 63 AZILECT R 63 double blind placebo 63 Plicera 63 Fibrillex TM 63 PFO migraine 63 viral kinetic 63 relapsed multiple myeloma 63 Azedra 63 oral deforolimus 63 RSD# oral 63 placebo controlled randomized 63 Ostarine 63 multicentre randomized 63 TASKi2 63 randomized placebo controlled 63 huC# DM4 63 TMC# [002] 63 Fodosine 63 HGS# 63 deforolimus 63 MEND CABG II 63 ANCHOR trial 63 Locteron ® 63 Pivotal Phase III 63 TBC# 63 EchoCRT 63 KRN# 63 selective androgen receptor modulator 63 Proxinium TM 63 EDEMA3 63 SYMMETRY trial 63 PSN# [002] 63 alvimopan 63 PHX# 63 IND submission 63 IND enabling 63 SPIRIT FIRST 63 refractory metastatic colorectal cancer 63 dose cohort 63 PRE SURGE 63 multicenter randomized double 63 midstage trials 63 Phase 1b clinical trials 63 PD LID 63 dyskinesia PD LID 63 multicenter randomized Phase 63 active comparator 63 dacetuzumab 63 pharmacokinetics PK 63 oral prodrug 63 II Clinical Trial 63 lorvotuzumab mertansine 63 LymphoStat B TM 63 fidaxomicin Phase 3 63 NO# [002] 63 phase III ACCLAIM 63 Phase #b/#a trial 63 IMA# 62 L BLP# 62 Asentar 62 Phase IIb kidney transplant 62 CHAMPION PCI 62 trastuzumab DM1 T DM1 62 rNAPc2 62 hypoxia activated prodrug 62 pertuzumab 62 PRT# 62 Azedra TM 62 TELINTRA 62 GLP toxicology studies 62 elagolix 62 multicenter Phase III 62 PANVAC VF 62 tolerability 62 ZYBRESTAT 62 TELCYTA 62 sunitinib malate 62 ozarelix 62 Viramidine 62 octreotide implant 62 Ocrelizumab 62 OvaRex ® MAb 62 AeroLEF TM 62 COMFORT II 62 lintuzumab 62 RELOVAIR ™ 62 EFAPROXYN 62 metastatic hormone refractory 62 multicenter 62 randomized clinical 62 MAGE A3 ASCI 62 ofatumumab HuMax CD# 62 hormone refractory prostate cancer 62 celgosivir 62 subcutaneous formulation 62 PS# DARA 62 trastuzumab emtansine T DM1 62 R#/MEM # 62 TKM ApoB 62 Triolex 62 Phase III Clinical Trial 62 investigational humanized monoclonal antibody 62 TLK# 62 Factor VIIa 62 Phase III psoriasis 62 histone deacetylase HDAC inhibitor 62 interferon gamma 1b 62 Phase #/#a clinical 62 double blinded randomized 62 IMPACT IMmunotherapy 62 Phase III randomized 62 investigational pan BCR 62 PEG SN# 62 teriflunomide 62 Cloretazine ® 62 AEG# 62 Phase III placebo controlled 62 initiate Phase 62 EndoTAG TM -1 62 QNEXA 62 Omigard 62 APPRAISE 62 Troxatyl 62 randomized multicenter Phase III 62 MERLIN TIMI 62 HGS ETR2 62 Shigamabs ® 62 IIa clinical 62 Zybrestat 62 unblinding 62 Mipomersen 62 Amigal 62 LibiGel ® 62 Vernakalant 62 Phase IIb Trial 61 ONCONASE R 61 torezolid phosphate 61 Phase 2a clinical trials 61 blinatumomab 61 NOX E# 61 Dextofisopam 61 QLT# 61 IIb clinical trial 61 preclinical efficacy 61 PS# [001] 61 initiate Phase 2b 61 Investigational Device Exemption IDE 61 eniluracil 61 pradefovir 61 HCV RESPOND 2 61 Locteron 61 multicenter prospective 61 Initiate Phase 61 talactoferrin 61 ToGA 61 Quinamed 61 Sym# 61 INCB# [002] 61 zalutumumab 61 picoplatin 61 OncoVEX GM CSF 61 omacetaxine mepesuccinate 61 albinterferon alfa 2b 61 PSMA ADC 61 Nuvion 61 PF # [002] 61 NGX# 61 MEK inhibitor 61 Cloretazine R VNP#M 61 initiate Phase Ib 61 preclinical studies 61 trial evaluating PRX# 61 Alocrest 61 HuMax EGFr 61 MBP# [001] 61 incyclinide 61 Phase III VISTA 61 ABSORB clinical 61 bardoxolone 61 liposomal formulation 61 PRIMO CABG 61 MAXY alpha 61 blinded randomized placebo controlled 61 custirsen 61 dose escalation 61 docetaxel Taxotere R 61 Safinamide 61 tolevamer 61 Marqibo 61 obatoclax 61 Traficet EN 61 Laquinimod 61 PROVENGE sipuleucel T 61 cell lymphoma CTCL 61 investigational oral 61 CR# vcMMAE 61 satraplatin Phase 61 Ereska 61 PXD# 61 safinamide 61 initiate Phase 1b 61 compound INCB# 61 Cimzia TM 61 Nexavar sorafenib 61 thorough QT 61 ACTEMRA TM 61 metastatic castration resistant 61 RG# [001] 61 GAMMAGARD 61 prospective multicenter 61 DR Cysteamine 61 Phase #/#a trial 61 ACAPODENE 61 Phase 2b randomized 61 alemtuzumab Campath 61 TASKi3 61 Oxypurinol 61 ruxolitinib 61 Genz # 61 Pimavanserin 61 PREOS R 61 huN# DM1 61 BLA submission 61 PDX pralatrexate 61 nalbuphine ER 61 ATL# [001] 61 tramiprosate Alzhemed TM 61 midstage studies 61 ELND# 61 pharmacokinetic studies 61 label multicenter 61 controlled multicenter 61 RSD# 61 enzastaurin 61 evaluating tivozanib 61 Initiated Phase 61 Diamyd ® 61 volociximab 61 initiated Phase Ib 61 ofatumumab 61 dirucotide MBP# 61 Phase 2b monotherapy 61 Virulizin R 61 varespladib 61 treatment naive genotype 61 Aryplase 61 Gabapentin GR 61 HCD# [002] 61 ILLUMINATE 61 refractory gout 61 BLOOM DM 60 aclidinium bromide 60 davunetide intranasal AL 60 Phase III Pivotal 60 CIMZIA TM certolizumab pegol 60 CRLX# 60 Parkinson disease levodopa induced 60 afatinib 60 European Sepsis Trial 60 XIENCE V Stent System 60 ganetespib 60 BLA filing 60 Board DSMB 60 ZYBRESTAT fosbretabulin 60 midstage clinical 60 BST CarGel R 60 Ophena TM 60 Annamycin 60 pralatrexate injection 60 AZILECT ® 60 non nucleoside inhibitor 60 Tocosol Paclitaxel 60 budesonide foam 60 ASA# 60 crizotinib PF # 60 Phase III HEAT 60 MINDSET 60 Personalized Immunotherapy 60 Sibutramine Cardiovascular Outcomes 60 ISIS # 60 blind randomized placebo 60 RDEA# 60 Bronchitol 60 CIMZIA TM 60 LymphoStat B 60 multicenter randomized 60 IL# PE#QQR 60 fosbretabulin 60 Dapagliflozin 60 ICA # 60 senicapoc 60 ORMD 60 elacytarabine 60 IMPACT DCM clinical 60 Sulonex 60 efficacy endpoint 60 Capesaris 60 TRO# 60 PEARL SC 60 Memryte 60 Tarceva TM 60 Fibrin Pad 60 HCV protease inhibitor 60 evaluating Actimmune 60 tivozanib 60 HCV SPRINT 60 prospective multicenter randomized 60 EOquin 60 CRx 60 Phase III Trial 60 EOquin TM 60 Elagolix 60 dose cohorts 60 MAA submission 60 Augment Injectable 60 MOZOBIL 60 generation PNP inhibitor 60 oxymorphone ER 60 Serdaxin 60 Pirfenidone 60 lintuzumab SGN 60 GetGoal Phase III 60 castrate resistant prostate cancer 60 Zelrix 60 Allovectin 7 60 VELCADE melphalan 60 Acapodene 60 FOLOTYN 60 dexanabinol 60 lumiliximab 60 trodusquemine 60 interferon beta 1b 60 LCP Tacro 60 Urocidin 60 velafermin 60 mertansine 60 diarrhea predominant irritable 60 Sular formulation 60 Viprinex TM 60 AEZS 60 Cleviprex TM clevidipine 60 generation purine nucleoside 60 GSK# [002] 60 ALN RSV# 60 Prostate AdenoCarcinoma Treatment 60 prospective randomized placebo 60 EDEMA4 60 VEGF Trap 60 ALN TTR# 60 SCH # 60 multicenter randomized controlled 60 Trizytek 60 ProSavin 60 Tavocept 60 Pivotal Trial 60 mapatumumab 60 PEG Interferon lambda 60 ataluren 60 visilizumab 60 Phase III ALLEGRO 60 HuMax CD4 60 PRECiSE 60 MGCD# [001] 60 SNT MC# 60 methylnaltrexone 60 CLIRS trial 60 Microplasmin 60 UPLYSO 60 RE LY 60 Phase 60 metastatic castrate resistant 60 perifosine 60 CLARITY study 60 dimebon 60 multicenter placebo controlled 60 XL# SAR# 60 masked placebo controlled 60 CoFactor 60 Hsp# inhibitor 60 PRECISE trial 60 Onalta ™ 60 Randomized Phase 60 Anturol TM 60 OHR/AVR# 60 neratinib 60 cathepsin K inhibitor 60 IMGN# 60 Phase lll 60 Exherin TM 60 randomized controlled multicenter 60 ONCONASE 60 daclizumab 60 TACI Ig 60 ularitide 60 RE SURGE 60 ITAX 60 ABSORB trial 60 Azilect ® 60 Daclizumab 60 Æterna Zentaris 60 Ixempra 60 riociguat 60 Phase 2b Clinical Trial 60 Ventavis 60 pharmacodynamic PD 60 BETAS 60 MyVax R 60 Veronate 60 Icatibant 60 ancrod 60 PARTNER Trial 60 metastatic HRPC 60 Diabetic Macular Edema 59 desvenlafaxine succinate 59 darusentan 59 antibody MAb 59 pharmacodynamics 59 DSMB recommended 59 6R BH4 59 VNP#M 59 Canvaxin 59 randomized controlled 59 NDA submission 59 Dyloject TM 59 Phase III ThermoDox 59 Zenvia TM 59 New Drug IND 59 HuMax CD# 59 ENDEAVOR IV 59 SUTENT ® 59 RhuDex ® 59 MYDICAR ® 59 Pivotal Phase 59 ZACTIMA 59 randomized double 59 anticancer compound 59 Spiegelmer ® 59 doxorubicin Transdrug ® 59 arzoxifene 59 ENDEAVOR III 59 BAY #-# 59 PNP inhibitor 59 HspE7 59 painful diabetic neuropathy 59 Matrix Phase 2b 59 neurogenic orthostatic hypotension 59 TOCOSOL Paclitaxel 59 Onconase 59 tezampanel NGX# 59 ThermoDox R 59 pseudobulbar affect PBA 59 mGluR5 negative 59 severe hypercholesterolemia 59 mTOR inhibitor 59 LCP AtorFen 59 Amplimexon 59 Phase IIB clinical 59 ARISE Phase III 59 zanolimumab 59 Phase IIb Clinical Trial 59 Elocalcitol 59 Denufosol 59 metaglidasen 59 ORENCIA ® 59 Telcyta 59 palifosfamide 59 Omacetaxine 59 Staccato loxapine 59 FTY# fingolimod 59 Cetrorelix 59 tremelimumab 59 recurrent glioblastoma multiforme 59 refractory chronic lymphocytic 59 randomized blinded 59 rALLy trial 59 KNS # 59 Desmoteplase 59 CCX# B 59 recurrent malignant glioma 59 Synavive 59 eltrombopag 59 AERx iDMS 59 ENRICH trial 59 randomized controlled clinical 59 receptor tyrosine kinase inhibitor 59 miconazole Lauriad ® 59 cutaneous T cell 59 Catena ® 59 SEPET TM 59 nonclinical studies 59 Gattex 59 oxypurinol 59 gemcitabine Gemzar ® 59 PEGPH# 59 CRMD# 59 R#/MEM 59 IMC #B 59 GATTEX 59 Betaferon ® 59 NASDAQ ARRY 59 EVEREST II 59 MDV# 59 aflibercept 59 EMPHASIS HF trial 59 CBLC# 59 AVASTIN 59 PrevOnco ™ 59 Nasdaq MAPP 59 Dalbavancin 59 IMPACT DCM 59 nitazoxanide 59 ThermoDox ® 59 abiraterone acetate 59 RoACTEMRA 59 CCX# 59 evaluating REVLIMID 59 CATIE AD 59 Multiple Ascending Dose 59 MAP# 59 Pivotal Study 59 SinuNase 59 Cloretazine 59 cetuximab Erbitux 59 Genasense ® 59 Ambrisentan 59 Tarvacin TM 59 randomized blinded placebo 59 telomerase inhibitor drug 59 maribavir 59 Maximum Tolerated Dose 59 CUSTOM III 59 sNDA submission 59 AIR CF1 59 TASQ 59 prospective randomized multicenter 59 XL# [003] 59 Iluvien ® 59 VA# [002] 59 seliciclib CYC# 59 Ozarelix 59 HuLuc# 59 Luveniq 59 Neurodex 59 iniparib 59 Nasdaq RDEA 59 belinostat 59 Combination REOLYSIN R 59 AVADO 59 Stimuvax 59 Cannabinor 59 NATRECOR R 59 Itopride 59 PROPEL trial 59 balsalazide tablet 59 goserelin 59 Biologics License Application BLA 59 lead Aganocide compound 59 IDX# 59 Serada 59 Clolar ® 59 IIa trials 59 Nasdaq HALO 59 ecallantide 59 ACOMPLIA R 59 UVIDEM 59 Sorafenib HCC Assessment 59 ARDIS 59 rindopepimut 59 lixisenatide 59 StemEx R 59 REOLYSIN ® 59 TEMSO 59 vosaroxin 59 Civacir 59 urocortin 2 59 radiation sensitizer 59 ospemifene 59 CDP# 59 Proellex TM 59 Vascular Wrap 59 SNT-MC#/idebenone 59 LibiGel Phase III 59 alfimeprase 59 amrubicin 59 inhibitor RG# 59 mCRC 59 leading oral taxane 59 registrational studies 59 dextofisopam 59 Nasulin 59 unblind 59 dexpramipexole 59 REMINYL ® 59 ThGRF 59 BCIRG 59 GOUT 59 SPIRIT III 59 Zoraxel 59 SAR# [004] 59 Insegia 59 budiodarone 59 AIR CF2 59 ALTU 59 orBec 59 velafermin belinostat 58 LE SN# 58 cangrelor 58 Aflibercept 58 allosteric modulator NAM 58 Oral NKTR 58 PRECISE Trial 58 edoxaban 58 metastatic sarcomas 58 HER2 positive metastatic breast 58 AIMM trial 58 candesartan cilexetil 58 VALOR trial 58 Phase 2b Trial 58 CA9 SCAN 58 Orazol 58 novel histone deacetylase 58 Solazed 58 valopicitabine 58 NEBIDO 58 iloperidone 58 OncoGel 58 voreloxin 58 PRTX 58 alagebrium 58 plus prednisone 58 MIRCERA 58 Biologics License Application 58 injectable enzyme 58 Aclidinium 58 personalized immunotherapy 58 sorafenib Nexavar 58 metastatic renal cell 58 Ceflatonin R 58 vilazodone 58 Genasense ® oblimersen 58 tesetaxel 58 clevudine 58 tafamidis 58 YONDELIS 58 OLYMPIA registry 58 ASCEND HF 58 NASDAQ CXSP announced 58 multicenter multinational 58 mipomersen 58 ARRY 58 C1 INH 58 rilonacept 58 peginesatide 58 rasagiline tablets 58 pharmacokinetic 58 metastatic CRPC 58 nab paclitaxel 58 oral methylnaltrexone 58 Prestara 58 MYDICAR 58 PROMACTA 58 CCR5 antagonist 58 ONTARGET 58 ZOLINZA 58 DB# [003] 58 label dose escalation 58 sapacitabine 58 adecatumumab 58 Initiates Phase II 58 oral treprostinil 58 Panzem R 58 lorcaserin Phase 58 carfilzomib 58 Loramyc R 58 microplasmin 58 Bezielle 58 topical formulation 58 Rezular 58 treatment naïve genotype 58 randomized multicentre 58 Tanespimycin 58 retinal vein occlusion induced 58 acyclovir Lauriad ® 58 Spheramine 58 drug eluting coronary stent 58 XL# XL# XL# 58 relapsing remitting multiple sclerosis 58 VITAL Trial 58 Ophena 58 Ceflatonin 58 Clonicel 58 BIBW 58 Inhalation Solution 58 AIM HIGH 58 ALN TTR 58 sulodexide 58 AZX# 58 Phase III ADT 58 nucleotide analog 58 Onrigin 58 multicentre randomized double 58 vandetanib 58 pediatric glioma 58 dependent kinase inhibitor 58 MNTX 58 THALOMID 58 ponatinib 58 investigational protease inhibitor 58 INSPIRE Trial Phase III 58 investigational hepatitis C 58 sodium thiosulfate STS 58 Vicinium TM 58 ACTIVE W 58 oral rivaroxaban 58 Fentanyl TAIFUN R 58 PROSTVAC TM 58 Myocet 58 ulimorelin 58 maximally tolerated dose 58 LymphoStat B belimumab 58 APEX AMI trial 58 GED aPC 58 HCV NS5B polymerase 58 dosing cohort 58 induced macular edema 58 compound PMX # 58 GRN#L 58 Relovair 58 BrachySil TM 58 sitaxsentan 58 bosutinib 58 safety tolerability 58 relapsing multiple sclerosis 58 resminostat 58 blinded placebo controlled 58 STRIDE PD 58 Allovectin 7 R 58 Stimuvax R 58 tramiprosate ALZHEMED TM 58 targeted radiotherapeutic 58 TOLAMBA 58 TRANSFORMS 58 Marketing Authorization Application MAA 58 EVIZON TM 58 GATTEX ® 58 Virulizin ® 58 DASISION 58 liprotamase 58 oral formulation 58 cutaneous T 58 Xcellerated T Cells 58 Azixa 58 romidepsin 58 ProLindac 58 motavizumab 58 Darusentan 58 GEM OS1 58 tasimelteon 58 SILENOR TM 58 modified REGENESIS Phase IIb 58 Tyrima 58 LEP ETU 58 ILUVIEN ® 58 Vectibix panitumumab 58 Tovaxin 58 IMC A# 58 Nexavar ® 58 vicriviroc 58 safety tolerability pharmacokinetics 58 davunetide 58 CRD5 58 mitogen activated ERK kinase 58 PLX PAD 58 VIAject 58 talabostat 58 TAXUS Element Stent System 58 Aeroquin 58 Reolysin 58 ACTEMRA 58 Anturol ® 58 INTERCEPT platelets 58 Panzem 58 Medidur TM FA 58 RhuDex 58 cystinosis patients 58 ANAVEX #-# [003] 58 Amoxicillin PULSYS Phase III 58 Phase 2a Clinical Trial 58 dose dose escalation 58 candidate Zenvia 58 symptomatic BPH 58 CALGB # [002] 58 DXL# 58 Alpharadin 58 Trofex 58 inhaled formulation 58 CA4P 58 Aplidin 58 ORENCIA R 58 Randomized Phase II 58 FavId 58 eprotirome 58 monotherapy 58 evaluating RDEA# 58 Phenserine 58 Phase III registrational 58 initiated Phase 1b 58 laquinimod 58 Shigamabs R 58 rhIGF-I/rhIGFBP-3 58 oral salmon calcitonin 58 Cethromycin 58 mGluR5 NAM 58 depsipeptide 58 IPX# 58 dosing cohorts 58 T Pred 58 PF # [001] 58 investigational antiplatelet agent 58 systemic RNAi therapeutic 58 otelixizumab 58 ORAL Sync 58 acyclovir Lauriad R 58 TPI ASM8 58 refractory AML 58 intravenous formulation 58 oral calcitonin 58 PROSTVAC ® 58 ascending dose

Back to home page